Suppr超能文献

抑制试验作为抗甲状腺药物治疗甲状腺功能亢进症预后指导的价值(作者译)

[Value of suppression test as a guide to prognosis of hyper-thyroidism treated with anti-thyroid drugs (author's transl)].

作者信息

Foldenauer A, Marquart F

出版信息

Dtsch Med Wochenschr. 1975 Mar 28;100(13):678-9. doi: 10.1055/s-0028-1106277.

Abstract

23 out of 42 suppression tests in 39 hyperthyroid patients were positive. In these patients thyreostatic treatment was stopped. In the follow-up period of 1-4 years hyperthyroidism recurred in 4 cases. Eight patients out of another group of 20 patients in whom antithyroid treatment was stopped after an equally long period without previous suppression testing also had a recurrence of hyperthyroidism. Frequency of relapses after antithyroid treatment can thus be diminished considerably if treatment is stopped only after suppression of the thyroid has been demonstrated. Lack of suppression after 18 to 24 months of thyreostatic therapy is an indication for treatment with radioiodine or surgery.

摘要

39例甲亢患者的42次抑制试验中有23次呈阳性。这些患者停止了抗甲状腺治疗。在1至4年的随访期内,4例患者甲亢复发。另一组20例患者在同样长的时间后停止抗甲状腺治疗,且之前未进行抑制试验,其中8例患者也出现了甲亢复发。因此,如果仅在证实甲状腺受到抑制后才停止治疗,抗甲状腺治疗后复发的频率可大幅降低。抗甲状腺治疗18至24个月后缺乏抑制是进行放射性碘治疗或手术治疗的指征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验